Clinical Trial Update: Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly [Phase 4]

View source ↗

Summary

A Phase 4 trial by Novartis evaluated the efficacy of combining octreotide acetate with cabergoline in patients with acromegaly, and the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• CABERGOLINE (CABERGOLINE)
• OCTREOTIDE ACETATE (octreotide acetate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 4 | Status: COMPLETED